Moderna Inc. ($MRNA) Stock Forecast: Up 7.7% Today

What is Moderna Inc.?

Moderna Inc. (MRNA) is a biotechnology company recognized for its mRNA technology, prominently displayed through its COVID-19 vaccine development. The company's primary focus includes infectious diseases, oncology, and rare diseases, underlined by its dedication to advancing its pipeline and projecting revenue growth.

Why is Moderna Inc. going up?

MRNA stock is up 7.7% on Jan 13, 2026 14:41

• Moderna's positive momentum today is linked to updates shared at the 44th Annual J.P. Morgan Healthcare Conference. Notably, the company revealed optimistic revenue growth forecasts for 2026 and progress in advancing its late-stage pipeline.
• Investor confidence in Moderna was likely bolstered by expectations of potential product approvals for flu and flu/COVID combinations in 2026, alongside upcoming pivotal trial data releases in various therapeutic areas.
• The appointment of Moderna's CEO, Stephane Bancel, to the Board of Directors of Commonwealth Fusion Systems is seen as a positive move that highlights Bancel's expertise and the potential synergies between the two companies.
• The company's strategic focus on key therapeutic areas, coupled with the encouraging outlook presented at the conference, has generated optimism among investors and propelled Moderna's stock performance.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story (MRNA)

Moderna is undergoing a strategic shift, prioritizing infectious disease, oncology, and rare diseases with the goal of achieving cash break-even by 2028. The year 2026 is critical, with upcoming oncology catalysts like Intismeran/Keytruda Phase II and III readouts potentially influencing future revenue and valuation. Despite near-term revenue declines, Moderna maintains a speculative 'Buy' rating for long-term investors due to cost reductions and a maturing pipeline, supporting its 10% revenue growth guidance for 2026.

https://seekingalpha.com/article/4859100-moderna-v940-keytruda-data-vaccine-revenues-drive-high-risk-recovery-story

Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Moderna, Inc. announced business updates and pipeline progress at the 44th Annual J.P. Morgan Healthcare Conference. The company expects significant revenue growth in 2026, further reductions in operating expenses in 2027, and anticipates potential first approvals for flu and flu/COVID combination products in 2026, along with pivotal trial data readouts in oncology, rare disease, and infectious disease. Moderna also reported an increase in its year-end 2025 cash balance and detailed its late-stage pipeline, including advancements in seasonal vaccines, oncology therapeutics, and rare disease treatments.

https://www.providencejournal.com/press-release/story/19201/moderna-provides-business-and-pipeline-updates-at-44th-annual-j-p-morgan-healthcare-conference/

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

Dyne Therapeutics has appointed Vikram Karnani to its Board of Directors, bringing extensive commercial and executive leadership experience in rare disease and biopharmaceuticals. Karnani, the current CEO of Collegium Pharmaceutical and former leader at Horizon Therapeutics, will help guide Dyne towards commercialization and portfolio expansion. His expertise in launching products and driving growth is expected to be crucial as Dyne prepares for its first potential product launch in Q1 2027.

https://investingnews.com/dyne-therapeutics-appoints-vikram-karnani-to-board-of-directors/

JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year

The annual J.P. Morgan Healthcare Conference highlighted a transforming biotech landscape marked by increased M&A activity and the growing influence of Chinese biotechs, prompting some to call for a "Sputnik moment" for the US industry. Major pharmaceutical companies like Bristol Myers Squibb and Pfizer are strategizing to offset patent expirations and boost future growth, with Pfizer making a significant bet on obesity drugs. Meanwhile, companies such as Sarepta Therapeutics face scrutiny after failed drug trials and revised sales forecasts, reflecting the volatile nature of the industry for both established players and emerging biotechs.

https://www.biopharmadive.com/news/jpm26-china-biotech-pfizer-obesity-bristol-sarepta-elevidys-sales/809320/

Commonwealth Fusion Systems Appoints Stephane Bancel To Board

Commonwealth Fusion Systems (CFS), a leading private fusion company, announced that Stephane Bancel, Moderna Inc.'s CEO, has joined its Board of Directors as an Independent Member. Bancel, known for leading Moderna's COVID-19 vaccine development, brings expertise in scaling innovative technologies. He was also an early investor in CFS and aims to help commercialize fusion energy for global power demand.

https://www.citybiz.co/article/792124/commonwealth-fusion-systems-appoints-stephane-bancel-to-board/

Trending Today

Amplitude Inc. ($AMPL) Stock Forecast: Down 5.1% Today

DocuSign Inc. ($DOCU) Stock Forecast: Down 5.6% Today

Estee Lauder Companies Inc. (The) ($EL) Stock Forecast: Up 5.0% Today

Verizon Communications Inc. ($VZ) Stock Forecast: Down 2.0% Today

Zimmer Biomet Holdings Inc. ($ZBH) Stock Forecast: Down 2.3% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Down 2.5% Today

Royal Caribbean Cruises Ltd. ($RCL) Stock Forecast: Down 5.0% Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Down 5.1% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 5.5% Today

Moderna Inc. Price History

31.11.2025 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement, closing down 2.38% in the recent trading session, underperforming the broader market indices.
• The significant layoffs in the biotech industry, including at Moderna, may have contributed to investor concerns about the company's future growth prospects.
• Despite the recent dip, Moderna has shown strong performance over the past month, outpacing the Medical sector, indicating potential volatility in response to market news and events.
• The upcoming Investor Event – Analyst Day hosted by Moderna could provide insights into the company's strategic direction, potentially impacting investor sentiment and stock movement in the near future.

17.11.2025 - MRNA Stock was up 5.5%

• Moderna's bullish movement can be attributed to its participation in the prestigious J.P. Morgan Healthcare Conference, where it showcased its advancements in mRNA technology and its commitment to making a positive impact.
• The positive news of the CHMP backing EU approval for Moderna's new COVID-19 vaccine, mNexspike, for individuals aged 12 and older, also contributed to the stock's upward momentum.
• Despite Pfizer's disappointing revenue outlook affecting its stock and dragging down shares of vaccine rivals like Moderna, the overall market sentiment towards Moderna seems to have been buoyed by its continuous innovation and progress in developing new vaccines and therapies.
• Moderna's announcement of dosing the first patient in a Phase 1/2 study of an investigational T-cell engager for multiple myeloma further showcased the company's diversification and expansion into new treatment areas, adding to investor optimism.

08.00.2026 - MRNA Stock was down 5.3%

• Moderna experienced a bearish trend today, possibly due to investors taking profits following a recent surge in the stock price.
• The positive updates on Moderna's enhanced COVID-19 vaccine combating the LP.8.1 variant may have been factored into the stock price, prompting a sell-off after the announcement.
• Investor caution could be influenced by potential competition and legal issues affecting other biotech firms like BioNTech, which could impact Moderna's market standing and revenue in the future.
• While Moderna continues to make significant progress in vaccine development, short-term stock movements can be influenced by market dynamics and external factors.

18.11.2025 - MRNA Stock was up 5.1%

• Moderna's stock surged as a French study confirmed the effectiveness of its COVID-19 vaccine, showcasing a significant reduction in COVID-19 deaths among vaccinated individuals.
• The anticipation surrounding Moderna's presentation at the J.P. Morgan Healthcare Conference also contributed to the bullish momentum, highlighting the company's continued advancements in the healthcare sector.
• The broader biotech sector's positive performance, driven by successful clinical data, new drug launches, and increased M&A activity, further boosted Moderna's stock price.
• Despite facing some analyst skepticism and insider selling, Moderna's stock managed to outperform, showcasing investor confidence in the company's growth prospects and its position in the biotech industry.

23.11.2025 - MRNA Stock was down 8.8%

• Moderna CEO's decision to retain expiring stock options and show confidence in the company's recovery may have unsettled investors, contributing to the bearish movement.
• Increased stake by prominent institutional investors such as Thrivent Financial for Lutherans could signal faith in Moderna's future, but a director selling a large number of shares might have alarmed other investors.
• The funding from CEPI for a Phase 3 trial of Moderna's mRNA pandemic influenza vaccine candidate might have been overshadowed by short-term worries, impacting the stock price negatively.
• While the positive news regarding Biogen's sustained benefits for ALS patients did not have a direct influence on Moderna, it could have shifted attention and investments away from Moderna, leading to a decline in its stock performance.

23.11.2025 - MRNA Stock was down 5.0%

• Institutional investor, Thrivent Financial for Lutherans, notably increased its stake in Moderna by 600.7% in the second quarter, signaling strong institutional interest. However, concerns arose among investors due to a director selling a substantial number of shares, potentially contributing to the bearish movement.
• There are positive signs for Moderna's pipeline with the news of CEPI funding a pivotal Phase 3 trial for the company's mRNA pandemic influenza vaccine candidate. Despite this, profit-taking and worries about market saturation for vaccines could be influencing market activity.
• GSK PLC's positive quarterly earnings and guidance may have diverted investor attention from Moderna, impacting MRNA's stock performance negatively.
• The absence of specific adverse developments related to Moderna suggests that the market's bearish movement may stem from broader market sentiment or sector rotation rather than company-specific factors.

13.00.2026 - MRNA Stock was up 7.7%

• Moderna's positive momentum today is linked to updates shared at the 44th Annual J.P. Morgan Healthcare Conference. Notably, the company revealed optimistic revenue growth forecasts for 2026 and progress in advancing its late-stage pipeline.
• Investor confidence in Moderna was likely bolstered by expectations of potential product approvals for flu and flu/COVID combinations in 2026, alongside upcoming pivotal trial data releases in various therapeutic areas.
• The appointment of Moderna's CEO, Stephane Bancel, to the Board of Directors of Commonwealth Fusion Systems is seen as a positive move that highlights Bancel's expertise and the potential synergies between the two companies.
• The company's strategic focus on key therapeutic areas, coupled with the encouraging outlook presented at the conference, has generated optimism among investors and propelled Moderna's stock performance.

06.00.2026 - MRNA Stock was up 6.0%

• Moderna's stock observed a positive uptrend today due to encouraging updates on the company's vaccine progress and submissions for its seasonal influenza vaccine candidates.
• The recent funding from CEPI for a crucial Phase 3 trial on Moderna's mRNA-based H5 pandemic influenza vaccine reflects a strong vote of confidence in the company's technology and its potential role in global pandemic readiness.
• Regulatory filings for Moderna's mRNA-1010 seasonal influenza vaccine in significant markets like the U.S., EU, Canada, and Australia, supported by favorable Phase 3 trial results, have boosted investor confidence in the company's future growth prospects.
• Moderna's confirmed revenue outlook and forthcoming milestones, including the launch of multiple vaccines post-COVID-19, signal a solid long-term strategy that has resonated well with investors, underpinning the optimistic market sentiment towards the stock.

06.00.2026 - MRNA Stock was up 11.9%

• The rise in Moderna's stock today is linked to encouraging developments related to the company's vaccine technology:
• Funding from CEPI for a pivotal Phase 3 trial on Moderna's mRNA-based H5 pandemic influenza vaccine candidate indicates strong belief in the company's technology and its potential for global pandemic preparedness.
• Regulatory submissions for Moderna's seasonal influenza vaccine, mRNA-1010, in various countries, backed by favorable Phase 3 study results, underscore the company's dedication to broadening its vaccine range and addressing public health requirements.
• Moderna's focus on using mRNA technology to better align with changing flu strains and its dedication to keeping vaccine prices reasonable and ensuring equal access for lowto middle-income nations further increases investor confidence in the company's growth prospects.
• Positive clinical trial outcomes, advancements in regulatory processes, and strategic moves in vaccine creation collectively position Moderna as a significant player in the healthcare industry, boosting investor confidence and contributing to today's bullish market activity.

06.00.2026 - MRNA Stock was up 11.5%

• Moderna's stock price saw a significant upsurge today following the company's submission of regulatory filings for its seasonal influenza vaccine, mRNA-1010, in multiple countries. This announcement has sparked investor confidence in the expansion of Moderna's non-COVID product range and the growth potential of its flu vaccine.
• The rise in Moderna's stock price was also supported by BofA Global Research raising its price target for the company, indicating strong belief in its new product releases and future opportunities.
• Despite analysts maintaining a "Reduce" consensus rating on Moderna due to concerns about revenue decline and profitability, the positive updates on the flu vaccine submissions and cost-saving measures have overshadowed these reservations, propelling the stock's bullish performance today.
• A global market analysis forecast predicting substantial growth in the mRNA cancer vaccine biologic lines market has likely bolstered the optimistic sentiment surrounding Moderna, underlining its potential for further expansion and revenue generation in the biotech industry.

19.11.2025 - MRNA Stock was up 5.0%

• Moderna's bullish movement today could be attributed to the positive investor sentiment following its participation in the 44th Annual J.P. Morgan Healthcare Conference, where it showcased its developments in mRNA medicine.
• The news of receiving funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for its bird flu vaccine candidate might have also boosted investor confidence in Moderna's future prospects.
• Despite the muted revenues and growth concerns, the market seems to be focusing on the potential of Moderna's innovative approach to vaccine development, driving the bullish movement in the stock today.

24.11.2025 - MRNA Stock was down 5.7%

• Moderna’s stock saw a decline to approximately $32.29 after a surge in late December. Several factors contributed to this movement:
• Investor worries regarding bird flu funding from CEPI and the progress of Moderna's mNEXSPIKE vaccine evaluated by the European Medicines Agency.
• Scrutiny on the company's financial moves, which include securing a $1.5 billion loan and outlining 2026 growth targets.
• Analysts have an overall "Hold" consensus rating with an average 12-month target price of $33.25, reflecting a cautious stance on the stock.
• The recent uptick in Moderna’s stock was primarily due to enhanced liquidity and cost containment rather than fundamental business growth, leading some investors to sell and reap profits. The decision aligns with concerns about declining fundamentals, like terminating the CMV program, which could impact the company's future prospects and pipeline.
• Today's bearish movement in Moderna’s stock seems to stem from profit-taking post a recent rally, investor focus on key developments and funding, and uncertainties about the company’s strategic path amidst evolving market trends.